Few & Far Between: How Biotech Gets Built

By Chris O'Brien

Welcome to Few & Far Between! Melissa Alesse, President of Biorasi, is your host for fascinating conversations - from clinical research and policymakers to biotech innovators and industry leaders.... more

5

1515 ratings

Download on the App Store

Download on the App Store

Get it on Google Play

FAQs about Few & Far Between: How Biotech Gets Built:

How many episodes does Few & Far Between: How Biotech Gets Built have?

The podcast currently has 74 episodes available.

Few & Far Between: How Biotech Gets Built episodes:

October 27, 2021 Episode 13: Kelly Franchetti RN, SVP, Global Head Patient Insights and Strategy at YPrime
How has patient advocacy grown to become the driver of rare disease drug development? In today's episode of Biorasi's Few & Far Between podcast, host Marc Gas, PhD, welcomes Kelly Franchetti, RN, SVP at YPrime, to discuss where advocacy is headed and where it needs to go.
...more
51min
October 13, 2021 Episode 12: Effie Parks and Spela Mirosevic
Social media platforms and podcasts are spotlighting the untold stories of rare disease patients and their families. Find out more in today's Few & Far Between podcast episode. Biorasi's Becky Knockemus welcomes guests Effie Parks, host of the Once Upon a Gene podcast, and Špela Miroševič, co-founder and president of the CTNNB1 Foundation.
...more
47min
September 28, 2021 Episode 11: Rebecca Stewart and Nicola Miller from Rare Revolution Magazine
How important is transparency to the rare disease community? Today's full episode of Few & Far Between features Biorasi's Lindsey Rios, with guests Rebecca Stewart and Nicola Miller from Rare Revolution Magazine.
...more
35min
September 15, 2021 Episode 10: Sharon Terry, CEO Genetic Alliance
Why is the sharing of data so crucial to #raredisease research? Tune in for today's full episode of Few & Far Between. Episode 10 features Sharon Terry, CEO at Genetic Alliance and #pseudoxanthomaelasticum (PXE) advocate.
...more
45min
September 01, 2021 Episode 9: Zogenix, Inc.'s Dawn Blessing and J. Michael Graglia from SynGAP
Tune in for today's full episode of Few & Far Between. Episode 9 features Biorasi's Becky Knockemus, Zogenix, Inc.'s Dawn Blessing, and J. Michael Graglia from SynGAP Research Fund, discussing the importance of diagnosing #raredisease early and the critical step of sharing study data.
...more
48min
August 18, 2021 Episode 8: David Rose, Rare Disease Speaker and Advocate
On today's podcast, speaker and rare disease advocate David Rose talks with Biorasi's Dr. Raul Silveira about occipital horn syndrome and supporting rare disease patients in the workforce.
...more
42min
August 04, 2021 Episode 7: US Congressman Gus Bilirakis
On today's podcast, US Congressman Gus Bilirakis joins host Wayne Bowden to discuss the importance of rare disease awareness and treatment.
...more
39min
July 21, 2021 Episode 6: Dr. Mehool Patel and Dr. Dilhan Weeraratne, IBM Watson Health
On today's podcast, host Wayne Bowden joins Biorasi's Omar Ibrahim and IBM Watson Health HOPE team members Dr. Mehool Patel and Dr. Dilhan Weeraratne to discuss glioblastoma and the importance of real-world evidence in clinical research.
...more
40min
July 07, 2021 Episode 5: Will Maier, VP of Rare Disease, Drug Development Sciences at ICON plc
On today’s podcast, host Wayne Bowden, Vice President of Partnerships and Strategy at Biorasi, talks with Will Maier, VP of Rare Disease, Drug Development Sciences at ICON plc, about clinical trial engagement in the rare disease patient community.
...more
52min
June 23, 2021 Episode 4: Marianne Clancy, Executive Director at Cure HHT
On today’s podcast, host Wayne Bowden, Vice President of Partnerships and Strategy at Biorasi, talks with Marianne Clancy, Executive Director at Cure HHT, about the foundation and their goal of reducing the number of undiagnosed cases of HHT.
...more
39min

FAQs about Few & Far Between: How Biotech Gets Built:

How many episodes does Few & Far Between: How Biotech Gets Built have?

The podcast currently has 74 episodes available.